系统性红斑狼疮皮肤病变的干预措施：Cochrane 综述总结。
Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review.
机构信息
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
出版信息
JAMA Dermatol. 2022 Feb 1;158(2):200-201. doi: 10.1001/jamadermatol.2021.5485.
CLINICAL QUESTION
What is the efficacy of interventions for cutaneous disease in systemic lupus erythematosus (SLE) in randomized clinical trials (RCTs)?
BOTTOM LINE
Available RCT evidence on the management of cutaneous disease in SLE is sparse and of limited quality. Among traditional options, methotrexate and hydroxychloroquine have the strongest evidence compared with placebo in the end points of complete clinical response and number of clinical flares, respectively, while chloroquine appears noninferior to methotrexate in achieving complete clinical response.
临床问题
在随机临床试验（RCT）中，治疗系统性红斑狼疮（SLE）皮肤疾病的干预措施的疗效如何？
结论
SLE 皮肤疾病管理方面的现有 RCT 证据稀缺且质量有限。在传统治疗选择中，与安慰剂相比，甲氨蝶呤和羟氯喹在完全临床缓解和临床发作次数这两个终点方面具有最强的证据，而氯喹在实现完全临床缓解方面似乎不劣于甲氨蝶呤。
Zotero 插件